Skip Navigation

Coronavirus (COVID-19) information for Dana-Farber patients & families Learn more

Michael Hassett, MD, MPH


Medical Oncology

Make an Appointment
Watch Video

Physician

  • Physician
  • Associate Professor of Medicine, Harvard Medical School

Centers/Programs

Clinical Interests

  • Breast cancer

Diseases Treated

Contact Information

  • Appointments617-632-2175 (new)
    617-632-3800 (follow-up)
  • Office Phone Number617-632-3800
  • Fax617-632-1930

Board Certification:

  • Internal Medicine, 2001
  • Medical Oncology, 2005

Fellowship:

  • Dana-Farber/Partners CancerCare

Residency:

  • University of Rochester Medical Center/Strong Memorial Hospital, Chief Medical Resident
  • University of Rochester Medical Center/Strong Memorial Hospital, Internal Medicine

Medical School:

  • State University of New York, Buffalo School of Medicine

Research

Health services research, Breast oncology

The main focus of my work involves measuring and improving quality of care, assessing outcomes, evaluating spending, and characterizing the value of cancer care.  Current major research projects include evaluating the quality of care offered to minority and economically disadvantaged women with breast cancer using linked cancer registry-Medicaid claims data, developing algorithms that identify patients with recurrent cancer using claims/electronic health record data, and studying the impact of initial treatment decisions for DCIS on the odds and type of recurrence.  Recently, I have published on the adoption of gene expression profile testing and its association with the use of chemotherapy among women with hormone-receptor positive breast cancer.  The long term goals of my work are to understand how healthcare policies, systems of care, and reimbursement models improve quality, impact outcomes, and increase value.

Prospective Study Testing a Simplified Paclitaxel Premedication Regimen in Patients with Early Breast Cancer. Oncologist. 2021 Sep 02.
View in: PubMed

Time-Driven Activity-Based Costing in Breast Cancer Care Delivery. Ann Surg Oncol. 2021 Aug 10.
View in: PubMed

ASO Visual Abstract: Time-Driven Activity-Based Costing (TDABC) in Breast Cancer Care Delivery. Ann Surg Oncol. 2021 Aug 10.
View in: PubMed

Correction to: Factors associated with late risks of breast cancer-specific mortality in the SEER registry. Breast Cancer Res Treat. 2021 Aug; 189(1):305.
View in: PubMed

Clinical Inflection Point Detection on the Basis of EHR Data to Identify Clinical Trial-Ready Patients With Cancer. JCO Clin Cancer Inform. 2021 06; 5:622-630.
View in: PubMed

Artificial intelligence in oncology: Path to implementation. Cancer Med. 2021 06; 10(12):4138-4149.
View in: PubMed

Landscape Analysis of Oncology Mobile Health Applications. JCO Clin Cancer Inform. 2021 05; 5:579-587.
View in: PubMed

Factors associated with late risks of breast cancer-specific mortality in the SEER registry. Breast Cancer Res Treat. 2021 Aug; 189(1):203-212.
View in: PubMed

Population-based estimates of survival among elderly patients with brain metastases. Neuro Oncol. 2021 04 12; 23(4):661-676.
View in: PubMed

Leveraging mobile health technology and research methodology to optimize patient education and self-management support for advanced cancer pain. Support Care Cancer. 2021 Oct; 29(10):5741-5751.
View in: PubMed

Sociodemographic Factors Associated With Rapid Relapse in Triple-Negative Breast Cancer: A Multi-Institution Study. J Natl Compr Canc Netw. 2021 03 10; 19(7):797-804.
View in: PubMed

Twenty-year risks of breast cancer-specific mortality for stage III breast cancer in the surveillance, epidemiology, and end results registry. Breast Cancer Res Treat. 2021 Jun; 187(3):843-852.
View in: PubMed

Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: ASCO Guideline Update. J Clin Oncol. 2021 Feb 20; 39(6):685-693.
View in: PubMed

Empirical power comparison of statistical tests in contemporary phase III randomized controlled trials with time-to-event outcomes in oncology. Clin Trials. 2020 12; 17(6):597-606.
View in: PubMed

Association between the 21-gene recurrence score and isolated locoregional recurrence in stage I-II, hormone receptor-positive breast cancer. Radiat Oncol. 2020 Aug 17; 15(1):198.
View in: PubMed

Natural Language Processing to Ascertain Cancer Outcomes From Medical Oncologist Notes. JCO Clin Cancer Inform. 2020 08; 4:680-690.
View in: PubMed

Assessment of Temporal Selection Bias in Genomic Testing in a Cohort of Patients With Cancer. JAMA Netw Open. 2020 06 01; 3(6):e206976.
View in: PubMed

Avoiding Peg-Filgrastim Prophylaxis During the Paclitaxel Portion of the Dose-Dense Doxorubicin-Cyclophosphamide and Paclitaxel Regimen: A Prospective Study. J Clin Oncol. 2020 07 20; 38(21):2390-2397.
View in: PubMed

Neoadjuvant treatment strategies for HER2-positive breast cancer: cost-effectiveness and quality of life outcomes. Breast Cancer Res Treat. 2020 May; 181(1):43-51.
View in: PubMed

Management of Male Breast Cancer: ASCO Guideline Summary. JCO Oncol Pract. 2020 08; 16(8):e839-e843.
View in: PubMed

Management of Male Breast Cancer: ASCO Guideline. J Clin Oncol. 2020 06 01; 38(16):1849-1863.
View in: PubMed

Commentary: Creating a patient-centered decision aid for ductal carcinoma in situ. Breast J. 2020 07; 26(7):1498-1499.
View in: PubMed

Patterns of care for older patients with stage IV non-small cell lung cancer in the immunotherapy era. Cancer Med. 2020 03; 9(6):2019-2029.
View in: PubMed

Characteristics and Outcome of AKT1E17K-Mutant Breast Cancer Defined through AACR Project GENIE, a Clinicogenomic Registry. Cancer Discov. 2020 04; 10(4):526-535.
View in: PubMed

Statistical Test/Estimation Methods Used in Contemporary Phase III Cancer Randomized Controlled Trials with Time-to-Event Outcomes. Oncologist. 2020 02; 25(2):91-93.
View in: PubMed

Statistical Test/Estimation Methods Used in Contemporary Phase III Cancer Randomized Controlled Trials with Time-to-Event Outcomes. Oncologist. 2019 Nov 19.
View in: PubMed

Assessment of Deep Natural Language Processing in Ascertaining Oncologic Outcomes From Radiology Reports. JAMA Oncol. 2019 Oct 01; 5(10):1421-1429.
View in: PubMed

Spending for Advanced Cancer Diagnoses: Comparing Recurrent Versus De Novo Stage IV Disease. J Oncol Pract. 2019 07; 15(7):e616-e627.
View in: PubMed

Performance of Cancer Recurrence Algorithms After Coding Scheme Switch From International Classification of Diseases 9th Revision to International Classification of Diseases 10th Revision. JCO Clin Cancer Inform. 2019 03; 3:1-9.
View in: PubMed

Determining the Time of Cancer Recurrence Using Claims or Electronic Medical Record Data. JCO Clin Cancer Inform. 2018 12; 2:1-10.
View in: PubMed

What drives variation in spending for breast cancer patients within geographic regions? Health Serv Res. 2019 02; 54(1):97-105.
View in: PubMed

Use of Patient-Reported Outcome Measures in Quality Oncology Practice Initiative-Registered Practices: Results of a National Survey. J Oncol Pract. 2018 10; 14(10):e602-e611.
View in: PubMed

How Do the Accrual Pattern and Follow-Up Duration Affect the Hazard Ratio Estimate When the Proportional Hazards Assumption Is Violated? Oncologist. 2019 07; 24(7):867-871.
View in: PubMed

Increasing Burden of Prior Authorizations in the Delivery of Oncology Care in the United States. J Oncol Pract. 2018 09; 14(9):525-528.
View in: PubMed

Medical Care Costs for Recurrent versus De Novo Stage IV Cancer by Age at Diagnosis. Health Serv Res. 2018 12; 53(6):5106-5128.
View in: PubMed

Comparing Survival After Recurrent vs De Novo Stage IV Advanced Breast, Lung, and Colorectal Cancer. JNCI Cancer Spectr. 2018 Apr; 2(2):pky024.
View in: PubMed

Estrogen-receptor status and risk of contralateral breast cancer following DCIS. Breast Cancer Res Treat. 2018 Oct; 171(3):777-781.
View in: PubMed

Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: ASCO Clinical Practice Guideline Focused Update. J Clin Oncol. 2018 08 10; 36(23):2433-2443.
View in: PubMed

Treating Second Breast Events After Breast-Conserving Surgery for Ductal Carcinoma in Situ. J Natl Compr Canc Netw. 2018 04; 16(4):387-394.
View in: PubMed

Chemotherapy medication errors. Lancet Oncol. 2018 04; 19(4):e191-e199.
View in: PubMed

Development, Validation, and Dissemination of a Breast Cancer Recurrence Detection and Timing Informatics Algorithm. J Natl Cancer Inst. 2018 03 01; 110(3):273-281.
View in: PubMed

Axillary vs Sentinel Lymph Node Dissection in Women With Invasive Breast Cancer. JAMA. 2018 01 16; 319(3):306.
View in: PubMed

Variation in guideline-concordant care for elderly patients with metastatic breast cancer in the United States. Breast Cancer Res Treat. 2018 Apr; 168(3):727-737.
View in: PubMed

Detecting Lung and Colorectal Cancer Recurrence Using Structured Clinical/Administrative Data to Enable Outcomes Research and Population Health Management. Med Care. 2017 12; 55(12):e88-e98.
View in: PubMed

Clinical risk score to predict likelihood of recurrence after ductal carcinoma in situ treated with breast-conserving surgery. Breast Cancer Res Treat. 2018 02; 167(3):751-759.
View in: PubMed

Usability Considerations in Oncology Electronic Medical Records. J Oncol Pract. 2017 08; 13(8):539-541.
View in: PubMed

Medicare Spending for Breast, Prostate, Lung, and Colorectal Cancer Patients in the Year of Diagnosis and Year of Death. Health Serv Res. 2018 08; 53(4):2118-2132.
View in: PubMed

Quality Improvement in the Era of Big Data. J Clin Oncol. 2017 10 01; 35(28):3178-3180.
View in: PubMed

Survival after recurrence of stage I-III breast, colorectal, or lung cancer. Cancer Epidemiol. 2017 08; 49:186-194.
View in: PubMed

Implementation of the 21-gene recurrence score test in the United States in 2011. Genet Med. 2016 10; 18(10):982-90.
View in: PubMed

Trends in the use of mastectomy in women with small node-negative breast cancer treated at US academic centers. Breast Cancer Res Treat. 2016 Feb; 155(3):569-78.
View in: PubMed

Characteristics of second breast events among women treated with breast-conserving surgery for DCIS in the community. Breast Cancer Res Treat. 2016 Feb; 155(3):541-9.
View in: PubMed

Challenges and Opportunities in Delivering High-Quality Cancer Care: A 2016 Update. Am Soc Clin Oncol Educ Book. 2016; 35:e294-300.
View in: PubMed

Variation in breast cancer care quality in New York and California based on race/ethnicity and Medicaid enrollment. Cancer. 2016 Feb 01; 122(3):420-31.
View in: PubMed

Detecting Lung and Colorectal Cancer Recurrence Using Structured Clinical/Administrative Data to Enable Outcomes Research and Population Health Management. Med Care. 2015 Jul 29.
View in: PubMed

Biological Subtype Predicts Risk of Locoregional Recurrence After Mastectomy and Impact of Postmastectomy Radiation in a Large National Database. Int J Radiat Oncol Biol Phys. 2015 Nov 01; 93(3):622-30.
View in: PubMed

Variation in type of adjuvant chemotherapy received among patients with stage I breast cancer: A multi-institutional study. Cancer. 2015 Jun 15; 121(12):1937-48.
View in: PubMed

Acute hospital care is the chief driver of regional spending variation in Medicare patients with advanced cancer. Health Aff (Millwood). 2014 Oct; 33(10):1793-800.
View in: PubMed

Validating billing/encounter codes as indicators of lung, colorectal, breast, and prostate cancer recurrence using 2 large contemporary cohorts. Med Care. 2014 Oct; 52(10):e65-73.
View in: PubMed

The relationship between quality, spending and outcomes among women with breast cancer. J Natl Cancer Inst. 2014 Oct; 106(10).
View in: PubMed

High-priority topics for cancer quality measure development: results of the 2012 American Society of Clinical Oncology Collaborative Cancer Measure Summit. J Oncol Pract. 2014 May; 10(3):e160-6.
View in: PubMed

Implementation of chemotherapy treatment plans (CTP) in a large comprehensive cancer center (CCC): The key roles of infrastructure and data sharing. J Clin Oncol. 2013 Nov; 31(31_suppl):20.
View in: PubMed

Utilization of cardiac monitoring tests in women with nonmetastatic breast cancer treated with trastuzumab. Per Med. 2013 Sep; 10(7):703-708.
View in: PubMed

What does breast cancer treatment cost and what is it worth? Hematol Oncol Clin North Am. 2013 Aug; 27(4):829-41, ix.
View in: PubMed

Do drug interaction alerts between a chemotherapy order-entry system and an electronic medical record affect clinician behavior? J Oncol Pharm Pract. 2014 Jun; 20(3):163-71.
View in: PubMed

Modeling the effectiveness of initial management strategies for ductal carcinoma in situ. J Natl Cancer Inst. 2013 Jun 05; 105(11):774-81.
View in: PubMed

Regional variation in spending and survival for older adults with advanced cancer. J Natl Cancer Inst. 2013 May 01; 105(9):634-42.
View in: PubMed

Cost of cancer care: The impact of disclosure on willingness to pay and treatment preferences. J Clin Oncol. 2012 Dec; 30(34_suppl):15.
View in: PubMed

Impact of oncology-related direct-to-consumer advertising: association with appropriate and inappropriate prescriptions. Cancer. 2013 Mar 01; 119(5):1065-72.
View in: PubMed

Improving electronic oral chemotherapy prescription: can we build a safer system? J Oncol Pract. 2012 Nov; 8(6):e168-73.
View in: PubMed

Initiation of adjuvant hormone therapy by Medicaid insured women with nonmetastatic breast cancer. J Natl Cancer Inst. 2012 Jul 18; 104(14):1102-5.
View in: PubMed

Pathologic characteristics of second breast cancers after breast conservation for ductal carcinoma in situ. Cancer. 2012 Dec 15; 118(24):6022-30.
View in: PubMed

Adoption of gene expression profile testing and association with use of chemotherapy among women with breast cancer. J Clin Oncol. 2012 Jun 20; 30(18):2218-26.
View in: PubMed

US Cancer Center Implementation of ASCO/Oncology Nursing Society Chemotherapy Administration Safety Standards. J Oncol Pract. 2012 Jan; 8(1):7-12.
View in: PubMed

Identifying women at risk of delayed breast cancer diagnosis. Jt Comm J Qual Patient Saf. 2011 Dec; 37(12):568-75.
View in: PubMed

Use of annual mammography among older women with ductal carcinoma in situ. J Gen Intern Med. 2012 May; 27(5):500-5.
View in: PubMed

Economic evaluation of targeted cancer interventions: critical review and recommendations. Genet Med. 2011 Oct; 13(10):853-60.
View in: PubMed

Relative dose intensity (RDI) assessment in an academic center. J Clin Oncol. 2011 Sep 20; 29(27_suppl):139.
View in: PubMed

Gene expression profile testing for breast cancer and the use of chemotherapy, serious adverse effects, and costs of care. Breast Cancer Res Treat. 2011 Nov; 130(2):619-26.
View in: PubMed

Adjuvant hormone therapy use in early-stage breast cancer patients insured by the New York State Medicaid program. J Clin Oncol. 2011 May 20; 29(15_suppl):6031.
View in: PubMed

The relationship between cost, quality, and outcomes among women with breast cancer in SEER-Medicare. J Clin Oncol. 2011 May 20; 29(15_suppl):6001.
View in: PubMed

Pathologic characteristics of second breast cancers (SBC) among women previously treated for ductal carcinoma in situ (DCIS) with breast conservation. J Clin Oncol. 2011 May 20; 29(15_suppl):1042.
View in: PubMed

Genomic testing and therapies for breast cancer in clinical practice. J Oncol Pract. 2011 May; 7(3 Suppl):e1s-7s.
View in: PubMed

Genomic testing and therapies for breast cancer in clinical practice. Am J Manag Care. 2011 May 01; 17(5 Spec No):e174-81.
View in: PubMed

Chemotherapy-related hospitalization among community cancer center patients. Oncologist. 2011; 16(3):378-87.
View in: PubMed

Impact of neoadjuvant chemotherapy on breast reconstruction. Cancer. 2011 Jul 01; 117(13):2833-41.
View in: PubMed

Using lifetime risk estimates to recommend magnetic resonance imaging screening for breast cancer survivors. J Clin Oncol. 2010 Sep 20; 28(27):4108-10.
View in: PubMed

The full burden of cancer. Oncologist. 2010; 15(8):793-5.
View in: PubMed

Clinical practice patterns and cost effectiveness of human epidermal growth receptor 2 testing strategies in breast cancer patients. Cancer. 2009 Nov 15; 115(22):5166-74.
View in: PubMed

Factors influencing changes in employment among women with newly diagnosed breast cancer. Cancer. 2009 Jun 15; 115(12):2775-82.
View in: PubMed

Breast cancer testing strategies and the utilization of targeted therapies: Data from the real world. J Clin Oncol. 2009 May 20; 27(15_suppl):e17518.
View in: PubMed

Admissions for chemotherapy-related serious adverse effects (CR-SAEs) and rates of mortality among community cancer center patients. J Clin Oncol. 2009 May 20; 27(15_suppl):6571.
View in: PubMed

Identifying high-priority quality measures for breast cancer quality improvement using data from a nationally representative sample. J Clin Oncol. 2009 May 20; 27(15_suppl):6507.
View in: PubMed

Disparities in breast cancer adjuvant chemotherapy: moving beyond yes or no. J Clin Oncol. 2009 May 01; 27(13):2120-1.
View in: PubMed

Breast biopsy patterns and outcomes in Surveillance, Epidemiology, and End Results-Medicare data. Cancer. 2009 Feb 15; 115(4):716-24.
View in: PubMed

Behavioral health services for women who have breast cancer. J Clin Oncol. 2009 Feb 10; 27(5):706-12.
View in: PubMed

Chemotherapy use for hormone receptor-positive, lymph node-negative breast cancer. J Clin Oncol. 2008 Dec 01; 26(34):5553-60.
View in: PubMed

Selecting high priority quality measures for breast cancer quality improvement. Med Care. 2008 Aug; 46(8):762-70.
View in: PubMed

Frequency and cost of chemotherapy-related serious adverse effects in a population sample of women with breast cancer. J Natl Cancer Inst. 2006 Aug 16; 98(16):1108-17.
View in: PubMed

Chemotherapy-related serious adverse events and health care expenditures among commercially insured women with breast cancer. J Clin Oncol. 2005 Jun; 23(16_suppl):6000.
View in: PubMed

Psychosis associated with hypopituitarism. Gen Hosp Psychiatry. 1998 Jul; 20(4):248-54.
View in: PubMed

Pathophysiology of congenital diaphragmatic hernia. XVI: Elevated pulmonary collagen in the lamb model of congenital diaphragmatic hernia. J Pediatr Surg. 1995 Aug; 30(8):1191-4.
View in: PubMed

Location

Dana-Farber Cancer Institute
450 Brookline Avenue
Boston, MA 02215
Get Directions

Ratings

Top